MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...

FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients two years of age ...

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...

FINTEPLA® (fenfluramine) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of ...

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include ...

– Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available ...

Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week blinded safety data Preliminary analyses presented at the European Academy of Dermatology & Venereology (EADV) ...

Jasper Therapeutics (JSPR) announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of ...

A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid ...

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...

LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...